Skye Bioscience (SKYE) Faces Class Action for Alleged Misleading Statements on Nimacimab

Skye Bioscience Faces Class Action Lawsuit Over Alleged Misleading Statements

Skye Bioscience, Inc. (NASDAQ: SKYE) is currently at the center of a class action lawsuit initiated by the DJS Law Group, which claims the company violated the Securities Exchange Act of 1934. The lawsuit specifically targets shareholders who purchased SKYE shares between November 4, 2024, and October 3, 2025. The complaint alleges that Skye made false and misleading statements regarding the efficacy of its lead product, nimacimab, leading investors to believe the product's clinical and commercial prospects were more promising than they were in reality. This misrepresentation, according to the lawsuit, has materially affected the value of Skye's stock and the potential recovery of affected investors.

Legal representatives from the DJS Law Group emphasize the importance of accountability in corporate governance, stating that misleading statements can severely undermine investor trust and market integrity. The group invites affected shareholders to participate in the recovery process, noting that seeking lead plaintiff status is not a prerequisite for claiming losses. The deadline for potential lead plaintiff appointments is January 16, 2026, which marks a critical date for investors looking to pursue compensation through this legal action. The DJS Law Group's focus on enhancing investor returns through legal advocacy positions them as a vigilant player in securities class actions.

Other law firms, including The Gross Law Firm and Levi & Korsinsky, LLP, have also issued notices urging Skye shareholders to come forward. These firms echo the claims of misleading communications related to nimacimab, asserting that such practices artificially inflated the company's stock value. Like the DJS Law Group, both firms emphasize that participating in the class action poses no financial risk to investors, as there are no out-of-pocket costs or fees for class members. These initiatives underline a growing concern within the legal community regarding transparency and accountability in the biotech sector, particularly as companies navigate complex clinical trials and regulatory approvals.

As the class action progresses, affected investors are encouraged to stay informed and consider their options for participation. The rise of legal claims in the biotech space highlights the importance of accurate information dissemination and the potential fallout of misleading investor communications. Skye Bioscience's future will likely be influenced by the outcome of these legal challenges and the company's ability to restore confidence among its shareholders.